Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apraclonidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.38 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apraclonidine SCHEMBL20840496 | 1.00 | CYP3A4 (0.39) | CYP3A4ALDH1A1TSHRADRA2AADRA2B | |
| Apraclonidine SCHEMBL22616253 | 0.98 | CYP3A4 (0.38) | CYP3A4ALDH1A1TSHRADRA2AADRA2B | |
| Apraclonidine SCHEMBL41138 | 0.98 | BLM (0.39) | CYP3A4ALDH1A1TSHRADRA2AADRA2B | |
| Apraclonidine SCHEMBL8762489 | 0.98 | BLM (0.39) | CYP3A4ALDH1A1TSHRADRA2AADRA2B | |
| Apraclonidine SCHEMBL22616315 | 0.90 | THRB (0.34) | CYP3A4ALDH1A1TSHRADRA2AADRA2B | |
| Apraclonidine SCHEMBL8891156 | 0.90 | THRB (0.34) | CYP3A4ALDH1A1TSHRADRA2AADRA2B | |
| Apraclonidine SCHEMBL22616231 | 0.90 | THRB (0.42) | CYP3A4ALDH1A1TSHRADRA2AADRA2B | |
| Apraclonidine SCHEMBL22616102 | 0.88 | THRB (0.41) | CYP3A4ALDH1A1TSHRADRA2AADRA2B | |
| Apraclonidine SCHEMBL22616234 | 0.87 | THRB (0.32) | CYP3A4ALDH1A1TSHRADRA2AADRA2B | |
| Apraclonidine SCHEMBL22616217 | 0.84 | KDM1A (0.32) | TSHRADRA2AADRA2BADRA2CNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7809 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144679-A1 | Vasoconstriction for eye treatments | BELKIN VISION LTD. (IL) | 2026-05-28 | — | — | US | claimed |
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| EP-4724839-A2 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | Mediprint Ophthalmics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724079-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Stealth BioTherapeutics Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260090984-A1 | CONTACT LENSES INCLUDING MEDICAMENTS AND METHODS OF MAKING AND USING SAME INCLUDING SLOW RELEASE OF GLAUCOMA TREATING DRUGS AND COMFORT ENHANCING DRUGS | MEDIPRINT OPHTHALMICS INC. (US) | 2026-04-02 | — | — | US | claimed |
| EP-4710918-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITION AND PREPARATION METHOD THEREFOR, OPHTHALMIC KIT CONTAINING OPHTHALMIC PHARMACEUTICAL COMPOSITION, AND USE | Shenyang Xingqi Pharmaceutical Co., Ltd. (CN) | 2026-03-18 | — | — | EP | claimed |
| US-12577562-B2 | Treatment of glaucoma with Rho Guanine Nucleotide Exchange factor 12 (ARHGEF12) inhibitors | REGENERON PHARMACEUTICALS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260048096-A1 | METHODS AND COMPOSITIONS FOR PRESERVING THE RETINAL OUTER NUCLEAR LAYER (ONL), PHOTORECEPTORS, AND RETINAL THICKNESS | STEALTH BIOTHERAPEUTICS INC. (US) | 2026-02-19 | — | — | US | claimed |
| EP-4683616-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING APRACLONIDINE FOR OCULAR REDNESS RELIEF | Alcon Inc. (CH) | 2026-01-28 | — | — | EP | claimed |
| EP-0365662-B1 | ANTIGLAUCOMA COMPOSITIONS CONTAINING COMBINATIONS OF ALPHA-2 AGONISTS AND BETA-BLOCKERS | ALCON LAB INC (US) | 1994-03-09 | — | — | EP | claimed |
| WO-1993025199-A1 | ALPHA-2-ADRENERGIC AGONISTS FOR TREATING PRESBYOPIA | TELOR OPHTHALMIC PHARMACEUTICALS, INC. (US) | 1993-12-23 | — | — | WO | claimed |
| WO-1993023082-A1 | TOPICAL OPHTHALMIC COMPOSITIONS COMPRISING A COMBINATION OF CALCIUM ANTAGONISTS WITH KNOWN ANTIGLAUCOMA AGENTS | ALCON LABORATORIES, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| EP-0550921-A1 | Pharmaceutical composition for ophthalmic use comprising a nonsteroidal anti-inflammatory and a decongestant drug | ZAMBON GROUP S.p.A. (IT) | 1993-07-14 | — | — | EP | claimed |
| US-5215991-A | Administering amiloride and an imidazolidine derivative | ALLERGAN, INC. (US) | 1993-06-01 | — | — | US | claimed |
| US-5180721-A | Imidazoline substituted naphthalene compounds for treatment of glaucoma | ALLERGAN, INC. (US) | 1993-01-19 | — | — | US | claimed |
| WO-1992021349-A1 | COMBINATIONS OF ALPHA-2 ADRENERGIC AGONISTS WITH ALPHA-3 ANTAGONISTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN, INC. (US) | 1992-12-10 | — | — | WO | claimed |
| EP-0507224-A2 | Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions | ALCON LABORATORIES, INC. (US) | 1992-10-07 | — | — | EP | claimed |
| EP-0429732-A1 | Sustained-release compositions containing cation exchange resins and polycarboxylic polymers | ALCON LABORATORIES, INC. (US) | 1991-06-05 | — | — | EP | claimed |
| EP-0399791-A1 | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure | ALLERGAN, INC (US) | 1990-11-28 | — | — | EP | claimed |